COVID-19 vaccine response under scrutiny in blood cancer patients
NCT ID NCT04830046
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This completed study looked at whether the COVID-19 vaccine triggers a strong immune response in 146 people with multiple myeloma or Waldenstrom's macroglobulinemia. Researchers measured antibody levels 28 days after the final vaccine dose. The goal was to see if these patients, whose immune systems are compromised, can mount effective protection from the vaccine.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
COVID-19 vaccine
What this could lead to
If successful, this could help doctors understand how well COVID-19 vaccines work in people with these blood cancers, guiding better vaccination strategies.
What could go wrong
This is an observational study, not a treatment trial. It only measures immune response, not whether the vaccine prevents infection. Results may not apply to all patients or vaccine types.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02215, United States